Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Adverse food reaction, Dyspnoea, Erythema, Psoriatic arthropathy
Clinical narrative: Psoriatic arthritis aggravated; Adverse food reaction; Difficulty breathing; Skin red; This spontaneous case was reported by a consumer and describes the occurrence of PSORIATIC ARTHROPATHY (Psoriatic arthritis aggravated) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis.   On 18-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In April 2021, the patient experienced DYSPNOEA (Difficulty breathing) and ERYTHEMA (Skin red). On an unknown date, the patient experienced PSORIATIC ARTHROPATHY (Psoriatic arthritis aggravated) (seriousness criterion medically significant) and ADVERSE FOOD REACTION (Adverse food reaction). At the time of the report, PSORIATIC ARTHROPATHY (Psoriatic arthritis aggravated) and ADVERSE FOOD REACTION (Adverse food reaction) was resolving and DYSPNOEA (Difficulty breathing) and ERYTHEMA (Skin red) outcome was unknown.            No concomitant medications were reported.  It was reported that, the patient did not eat soy, gluten due to reactions and had hard time breathing and reddening of skin.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  The reporter's causality for the event(s) of psoriatic arthritis flare up with Humira(adalimumab) was a reasonable possibility. the reporter's causality for the event(s) of "did not eat soy, gluten due to reactions was not provided. the reporter's causality for the event(s) of hard time breathing and reddening of skin after Covid vaccines" with Humira(adalimumab) was no reasonable possibility.  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment: This spontaneous case concerns a 40 year old male patient with concurrent condition of psoriatic arthritis, who experienced the unexpected serious (medically significant) event Psoriatic arthropathy (reported as Psoriatic arthritis aggravated), unknown days after receiving the second dose of mRNA-1273 vaccine. No information on exact date of the event, detailed clinical course, relevant investigations and treatment was available in the report. The event was resolving.  Concurrent condition of psoriatic arthritis could be confounding for the event.  The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 40 year old male patient with concurrent condition of psoriatic arthritis, who experienced the unexpected serious (medically significant) event Psoriatic arthropathy (reported as Psoriatic arthritis aggravated), unknown days after receiving the second dose of mRNA-1273 vaccine. No information on exact date of the event, detailed clinical course, relevant investigations and treatment was available in the report. The event was resolving.  Concurrent condition of psoriatic arthritis could be confounding for the event.  The benefit-risk relationship of mRNA-1273 is not affected by this report.